032918_SERV_NEWS.jpg

Servier CDMO Wins 11 CMO Leadership Awards

by Servier CDMO
Events, CMO Leadership Award

Servier CDMO is proud to announce we have been recognized across 11 categories in the 2018 CMO Leadership Awards, meeting or exceeding customer expectations in the core categories of Capabilities, Compatibility, Expertise, Quality, Reliability and Service, and receiving individual attribute awards in the areas of On-Time, Reputation, Right First Time, State-of-the-Art and Strength of Science.

Conducted annually by Life Science Leader to help pharmaceutical executives vet potential CMO partners, the CMO Leadership Awards are based solely on customer feedback, with respondents evaluating only companies with which they’ve worked on an outsourced project within the past 18 months. This year, 110 contract manufacturers were evaluated on 23 different performance metrics.

The awards are a testament to Servier CDMO’s commitment to providing the highest quality service leveraging 60 years of quality, know-how and reliability through Servier, a leading international pharmaceutical group with operations in 148 countries.

To learn more about the CMO Leadership Awards,
visit www.cmoleadershipawards.com.

Reducing Time to Market with Targeted Regulatory Affairs Support

Regulatory affairs activities are essential components of any drug development and commercialization program. CDMOs with extensive experience with product approvals that have regulatory affairs deeply integrated with other operational teams can provide optimized regulatory strategies.

Corporate Social Responsibility as a Driver for Improved Sustainability

 The pharmaceutical industry must respond to growing expectations for product safety, the conduct of clinical trials, access to therapeutic care and the environmental impact of medicinal products and manufacturing. Servier Group formalized its Corporate Social Responsibility (CSR) strategy to integrate and communicate the actions it is taking in collaboration with internal and external stakeholders.

Shire Announces Sale of Oncology Business to Servier for $2.4 Billion

Servier Group is proud to announce that it will develop its presence in the US market through the oncology therapeutic area. Servier CDMO, in accordance with the group’s strategy, continues to develop its services for High Potent drugs in API and drug product.